Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer


Series B | Dead

Total Raised


Last Raised


About Groove Biopharma

Groove Biopharma, fka Mirina Corporation, develops therapeutics using Minor Groove Binder Technology (MGB) to affect cellular processes involving microRNAs. Groove holds a license to the technology from Elitech for use in therapeutics. Elitech developed and patented novel methods for preparing oligonucleotides appended with chemical agents, that modify binding to target sequences in RNA or DNA. By incorporating this technology into miRNA therapeutics, Groove Biopharma's novel MGB-oligonucleotide compounds are anticipated to exhibit superior properties, such as enhanced target selectivity, better potency, and improved pharmacological activity. Groove Biopharma's technology presents promising potential for treating a wide range of diseases including cancers, infectious disease and metabolic disorders.

Groove Biopharma Headquarter Location

1616 Eastlake Ave. E. Suite 202

Seattle, Washington, 98102,

United States

Latest Groove Biopharma News

Accelerator Gets New Chief Scientist, David McElligott

Mar 29, 2012

XconomySeattle —  The Accelerator, the place that starts more biotech companies than any other outfit in Seattle, has had a changing of the scientific guard. David McElligott, the chief scientific officer at one of Accelerator’s portfolio companies, Groove Biopharma, has been promoted to the role of chief scientific officer at Accelerator. He replaces Pat Gray, who announced this week he’s moved to take a new job as a scientific fellow at Seattle-based Omeros (NASDAQ: OMER ). McElligott earned his stripes at Accelerator the past several years at Groove, which recently raised $6 million after hitting a series of milestones with its microRNA drug development programs. He’s a former senior director of biological sciences at Bothell, WA-based Icos, where he got to know Gray and several other scientists who have migrated over the years to Accelerator. The new job means that McElligott will have a broader role in day-to-day R&D decisions across the Accelerator portfolio, which currently includes three active companies— Oncofactor , Acylin Therapeutics , and Groove . He’ll also be involved in scouting new investments. David McElligott, Accelerator's chief scientific officer “David has consistently impressed the team and our investors with his professional, steady and thoughtful approach, his broad scientific and drug development expertise, his agility and his innovative instincts,” said Accelerator CEO Carl Weissman , in a statement. Gray added: “I have worked with David McElligott for 9 years both at Icos and Accelerator and could not think of a better person to whom to hand off the scientific reins.” Accelerator was founded in 2003 by the Institute for Systems Biology, Alexandria Real Estate Equities, and a network of venture investors that sought to bring scientific expertise, facilities, and capital together to help create more biotech companies with big potential. It has formed 12 startups since inception, four of which have spun out in one form or another as their own as independent venture-backed companies—Allozyne, Theraclone Sciences, VLST, and Integrated Diagnostics. The Accelerator is currently backed by Amgen Ventures, Arch Venture Partners, OVP Venture Partners, PPD, Alexandria Real Estate Equities, WRF Capital, and the Institute for Systems Biology. McElligott will be one of the featured speakers at the big Xconomy Seattle event next week, “ Reinventing Biotech’s Business Model .” He will be on hand along with Weissman to talk about how to keep the science progressing at Groove in an environment with limited venture capital.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Groove Biopharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Groove Biopharma is included in 4 Expert Collections, including Pharma Startups.


Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.


Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,708 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).



4,844 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.